What is VIR?
VIR Biotechnology is a clinical-stage immunology firm dedicated to leveraging immunologic insights and cutting-edge technologies to combat and prevent serious infectious diseases. Founded in 2016 and headquartered in San Francisco, California, the company is focused on developing a portfolio of therapies that harness the power of the immune system. Its strategic approach involves identifying key biological pathways and applying innovative technological platforms to address unmet medical needs in the infectious disease landscape. The company's commitment to scientific rigor and its focus on critical global health challenges position it as a key player in the biotechnology sector.
How much funding has VIR raised?
VIR has raised a total of $260M across 2 funding rounds:
Unspecified
$250M
Grant
$10M
Unspecified (2020): $250M with participation from GlaxoSmithKline
Grant (2023): $10M led by Bill & Melinda Gates Foundation
Key Investors in VIR
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a prominent organization focused on supporting global health and poverty reduction initiatives, likely aligning with VIR's mission to combat infectious diseases.
GlaxoSmithKline
GlaxoSmithKline (GSK) is a global biopharmaceutical company with a strong focus on vaccines and infectious diseases, indicating a strategic alignment with VIR's therapeutic areas.
What's next for VIR?
With the recent infusion of $10M in a major strategic investment, VIR is poised for accelerated growth and development. This substantial backing, part of its overall $260M in capital, will likely fuel the advancement of its clinical trials, expansion of its research and development initiatives, and potential strategic partnerships. The company's focus on infectious diseases, a critical area of global health, suggests a strategic direction aimed at addressing significant public health threats. VIR's trajectory indicates a move towards scaling its operations and potentially bringing its innovative therapies closer to market, marking a significant phase in its evolution as a clinical-stage biotechnology entity.
See full VIR company page
